|
|
|
| The Vaccination with Saccharomyces cerevisiae Recombined with Mycobacterium tuberculosis Antigens Induces Specific Immunoresponsesin Mice |
| LU Jian, JIAN Jia-xi, LIU Jian-ping, WANG Hong-hai |
| State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China |
|
|
|
Abstract Recently there were increasing reports about vaccines based on whole recombinant Saccharomyces cerevisiae. Mycobacterium tuberculosis (Mtb) protective antigens ESAT6 and Ag85B against tuberculosis were selected to be expressed in S. cerevisiae with pHR expression system. Two yeasts producing fusion proteins ESTA6-Ag85B (EA) and IFN-γ-ESAT6-Ag85B(IEA)respectively were constructed and the immune responses elicited by the recombinant yeasts were investigated in mice. Injection of mice subcutaneously with the recombinant yeasts induced Ag85B-specific IgG in high level and Th1 immune responses associated with IFN-γ and IL-2 secretion and no IL-4 production. Compared to BCG, Yeast-IEA vaccination stimulated significantly stronger immune response. It was confirmed that yeast could activated dendritic cells maturation with upregulation of co-stimulatory molecules and MHC molecules. The results suggest that the whole recombinant yeast (Yeast-IEA) may be an attractive candidate of vaccines against tuberculosis.
|
|
Received: 19 August 2014
Published: 25 November 2014
|
|
|
|
|
|
[2] Kaufmann S H. Tuberculosis vaccines: time to think about the next generation. Semin Immunol, 2013, 25(2):172-181.
[3] Kaufmann S H. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis, 2011,11:633-640.
[4] Rowland R, McShane H. Tuberculosis vaccines in clinical trials. Expert Rev Vaccines, 2011,10(5): 645–658.
[5] Celik E, Calik P. Production of recombinant proteins by yeast cells. Biotechnology Advances, 2012, 30:1108-1118.
[6] McAleer W J, Buynak E B, Maigetter R Z, et al. Human hepatitis B vaccine from recombinant yeast. Nature, 1984, 307:178-180.
[7] Stubbs A C, Martin K S, Coeshott C, et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nature medicine, 2001;7(5):625-629.
[8] Haller A A, Lauer G M, King T H, et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine, 2007, 25(8):1452-1463.
[9] Galao R P, Scheller N, Alves-Rodrigues I, et al. Saccharomyces cerevisiae: a versatile eukaryotic system in virology. Microbial Cell Factories, 2007,6:32-37.
[10] 江佳稀,张宇飞,沈洪波,等. 表达结核杆菌抗原的重组酿酒酵母免疫小鼠研究. 复旦学报(自然科学版), 2011,50(2):192-197.
Jiang J X,Zhang Y F, Shen H B,et al.Induction of antigenspecific humoral immune response by subcutaneous vaccination with Saccharomyces cerevisia expressing Mycobacterium tuberculosis antigen.Journal of Fudan University(Natural Science),2011,50(2):192197.
[11] Bernstein M B, Chakraborty M, Wansley E K, et al. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine, 2008, 26(4): 509-521.
[12] Remondo C, Ceredaa V, Mostbock S, et al. Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen. Vaccine, 2009, 27:987-994.
[13] Wansley E K, Chakraborty M, Hance K W, et al. Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clinical Cancer Research, 2008, 14(13):4316-4325.
[14] Dietrich J, Doherty T M. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development. APMIS, 2009, 117: 440-457.
[15] Sable S B, Verma I, Khuller G K, et al. Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis. Vaccine, 2005, 23: 4175-4184.
[16] Tsolaki A G, Nagy J, Leiva S, et al. Mycobacterium tuberculosis antigen 85B and ESAT-6 expressed as a recombinant fusion protein in Mycobacterium smegmatis elicits cell-mediated immune response in a murine vaccination model. Molecular Immunology, 2013, 54(3-4):278-283.
[17] Lalvani A, Sridhar S, von Reyn C F. Tuberculosis vaccines: time to reset the paradigm. Thorax, 2013, 68(12):1092-1094.
expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clinical Cancer Research, 2008, 14(13):4316-4325.
[18] Dietrich J, Doherty T M. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development. APMIS, 2009, 117: 440-457.
[19] Sable S B, Verma I, Khuller G K, et al. Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis. Vaccine, 2005, 23: 4175-4184.
[20] Tsolaki A G, Nagy J, Leiva S, et al. Mycobacterium tuberculosis anresponse in a murine vaccination model. Molecular Immunology, 2013, 54(3-4):278-283.
[21] Lalvani A, Sridhar S, von Reyn C F. Tuberculosis vaccines: time to reset the paradigm. Thorax, 2013, 68(12):1092-1094.
[22] Shortman K, Liu Y J. mouse and human dendritic cell subtypes. Nature Reviews Immunology, 2002, 2(3):151-161.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
